TI
VKTX icon

Tidal Investments’s Viking Therapeutics VKTX Stock Holding History

Tidal Investments’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000
Closed -$52.6K – 2367
2025
Q3 		$52.6K Buy
+2,000
New +$59.7K ﹤0.01% 2027

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Tidal Investments's VKTX Position: Q1 2026 in Review

Tidal Investments increased its Viking Therapeutics (VKTX) stake by 60% in Q1 2026, buying an estimated $477K and bringing the position to 39,554 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

Tidal Investments first reported a position in VKTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $2.37M in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Tidal Investments held 39,554 shares of Viking Therapeutics worth $1.29M as of Q1 2026.
  • Tidal Investments bought 14,834 Viking Therapeutics shares in Q1 2026, an estimated $477K.
  • Viking Therapeutics made up ﹤0.01% of Tidal Investments's portfolio in Q1 2026, its #1321 holding.
  • Tidal Investments first reported a position in Viking Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Tidal Investments's Viking Therapeutics position peaked at $2.37M in Q1 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Tidal Investments's 13F filing for Q1 2026, filed 15 May 2026.